DOCSLIB.ORG

Audit Report Sample(Rev.3)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Audit Report Sample(Rev.3) Report Number: QIP-ASI185768 Audit Date : 23 Oct.,2019 This report is issued by Focus Technology Co., Ltd. (Made-in-China.com) and the supervising inspectorate (SGS-CSTC Standards Technical Services Co., Ltd.) to confirm that: Company Name : Zhangqiu Yu Bin Petrochemical Fittings Factory 章丘市裕彬石化配件厂 Showroom : www.ybfactory.com Address : No. 54 Jiqing Road, Puji Town, Zhangqiu District, Jinan, Shandong, China Product : Forgings, Shaft, Tube Sheet, Forging Ring, CNC Machining Aluminum, Dish Head, Gear, Grinding Ball, Mould Base, Flange has been on site audited for the Following Scope of Activity 1. General Information 2. Foreign Trade Capacity 3. Product Research & Development Capacity 4. Management System and Product Certification 5. Production Capacity & Quality Control 6. Working Environment 7. Energy Saving and Emission Reduction 8. Photos General Comments: Zhangqiu Yu Bin Petrochemical Fittings Factory is a manufacturer with 92 employees; it was established in 1999, located in No. 54 Jiqing Road, Puji Town, Zhangqiu District, Jinan, Shandong, China. The workshops occupy an area of 9,000 square meters. They have obtained CE certificate. Zhangqiu Yu Bin Petrochemical Fittings Factory has successful foreign trading experience in North America, Europe, Mideast and etc. Sign for and on behalf of SGS-CSTC Standards Technical Services Co., Ltd. Page No.:1 1 of 22 SGS No: QIP-ASI185768 SUPPLIER ASSESSMENT REPORT Audited Company Zhangqiu Yu Bin Petrochemical Fittings Factory Audited Site: No. 54 Jiqing Road, Puji Town, Zhangqiu District, Jinan, Shandong, China Consigner of Made-in-China Assessment Audit Type Initial Audit Re-audit Audit Date 23 Oct.,2019 Verify Report www.sgs.com/ecv Auditor Ding Xu Reviewed by Simon Wang CONTENTS Part A: General Information Section 1: Company Overview Section 2: Human Resources Part B: Foreign Trade Capacity Section 1: Export Overall Situation Section 2: Export Business Capacity Section 3: Supplier Management Section 4: After-sales Service Capacity Part C: Product Research & Development Capacity Section 1: Product Research & Development Capacity Part D: Management System and Product Certification Section 1: Management System(s) and Product Certification Part E: Production Capacity & Quality Control Section 1: Production Capacity Section Section 2: Production Process Control Part F: Financial Position Section 1: Financial Data Section 2: Key Performance Indications Section 3: Banking Section 4: Product Insurance Part G: Working Environment Section 1: Working Environment Part H: Energy Saving and Emission Reduction Section 1: Environmental Management Section 2: Water, Gas and Noise Control Part I: Industry Information Section 1: Industry Information Part J: Photos Section 1: Photos of Documents Section 2: Photos of Company Page No.: 2 of 22 SGS No: QIP-ASI185768 Part A: General Information Section 1: Company Overview 1.1 Legal Validity Does the company have a valid Yes No Others Registration 91370181X138847499 business license? Number Year of established 12 May.,1999 Valid Date Long Valid Registered address Chizitou Village, Puji Sub-District Office, Zhangqiu District, Jinan, Shandong, China Actual address No. 54 Jiqing Road, Puji Town, Zhangqiu District, Jinan, Shandong, China Does the company in abnormal operation status list of industrial No and commercial bureau? Registered capital N/A Name of legal representative Mr. Pan Gao Manufacturing and sales of lathe accessories, flange, elbow, petrochemical accessories, agricultural machinery parts, hydraulic parts, mining machinery parts, metallurgical equipment parts (not including casting and forging); Sales of hardware, Business scope chemical products (excluding hazardous chemicals), steel, building materials, electronic products, machine tools, forging, casting; Import and export of goods and technologies.(The items which need to be authorized by the law can be operated only after the approval by relative department) 1.2 Basic Information Contact person Mr. Pan Gao Phone number 0086-531-83869369 Fax number 0086-531-83874238 URL/Web address www.ybfactory.com Manufacturer Trading Company Company type Combined Group Corporation Type of ownership Limited Company Public Company Foreign joint venture State-Owned Private Owner Wholly foreign-owned enterprises Associated company No Products manufactured / sold Forgings, Shaft, Tube Sheet, Forging Ring, CNC Machining Aluminum, Dish Head, scope Gear, Grinding Ball, Mould Base, Flange 1.3 Company Building Information According to: Land certificate Real estate certificate Lease agreement Observation Estimated on site The company area 10,000 square meters The land occupies 15,000 square meters. The offices occupy 1,000 square meters. The workshops occupy 9,000 square meters. Page No.: 3 of 22 SGS No: QIP-ASI185768 Section 2: Human Resources 2.1 Company Chart A B C D E F G 2.2 Explanation of Code and Employee Details Code Department Number of employees A GM 1 B Sales Dept. 9 C Production Dept. 75 D Finance Dept. 2 E QC Dept. 2 F R&D Dept. 1 G Purchase Dept. 2 Number in total: 92 2.3 Key Staff Working experience for this trade / Title Full name Education total experience GM Mr. Pan Gao University 16/16 years Remark: Above information of Key Staff was based on interview with company representative. Page No.: 4 of 22 SGS No: QIP-ASI185768 Part B: Foreign Trade Capacity Section 1: Export Overall Situation 1.1 Export Overall Situation Does the company have a valid Import and Export license? Yes No The import and export enterprise code. 91370181X138847499 within 1 year staff 1-5 years 3 staffs The number of foreign trading staff with relevant trading 6-10 years 4 staffs over 10 years 2 staffs experience. Total 9 staffs The language freely used by foreign trade staff English others Annual revenue of previous year Confidential Annual export revenue of previous year Confidential Estimated export revenue for this year. Confidential Overseas agent / branch Yes No Nearest port Qingdao Port Acceptable quotation terms FOB CIF CFR Acceptable payment terms LC T/T D/P PayPal Western Union Small-amount payment Average lead time (Peak Season) within 15 workday one month 2-3 months 4-6 months 6-12 months more time Average lead time (Off Season) within 15 workday one month 2-3 months 4-6 months 6-12 months more time Section 2: Export Business Capacity 2.1 Market Distribution (please list top three areas) Market Main Product Main client North America Forgings, Shaft, Tube Sheet, Forging Ring, CNC Confidential Machining Aluminum, Dish Head, Gear, Grinding Ball, Mould Base, Flange South America Forgings, Shaft, Tube Sheet, Forging Ring, CNC Confidential Machining Aluminum, Dish Head, Gear, Grinding Ball, Mould Base, Flange Europe Forgings, Shaft, Tube Sheet, Forging Ring, CNC Confidential Machining Aluminum, Dish Head, Gear, Grinding Ball, Mould Base, Flange Southeast Asia/ Mideast Forgings, Shaft, Tube Sheet, Forging Ring, CNC Confidential Machining Aluminum, Dish Head, Gear, Grinding Ball, Mould Base, Flange Africa Forgings, Shaft, Tube Sheet, Forging Ring, CNC Confidential Machining Aluminum, Dish Head, Gear, Grinding Ball, Mould Base, Flange East Asia (Japan/ South Forgings, Shaft, Tube Sheet, Forging Ring, CNC Confidential Korea) Machining Aluminum, Dish Head, Gear, Grinding Ball, Mould Base, Flange Australia Forgings, Shaft, Tube Sheet, Forging Ring, CNC Confidential Machining Aluminum, Dish Head, Gear, Grinding Ball, Mould Base, Flange Page No.: 5 of 22 SGS No: QIP-ASI185768 Domestic Others Page No.: 6 of 22 SGS No: QIP-ASI185768 Section 3: Supplier Management 3.1 Supplier Management Item Content Observations /Comments Does the company establish and implement Have the written procedures and followed records an effective suppliers’ assessment Have the written procedures but no records 1 procedure? Have relevant records without written procedure No written procedures or followed records Other Does the company have an updated list of The approved suppliers list was updated in 2017 approved suppliers? Have the written suppliers without approved signature or date. 2 Provided some suppliers names No approved suppliers list Other Section 4: After-sales Service Capacity 4.1 After-sales Service Capacity Item Content Observations /Comments Is there a procedure to conduct random Have clear standards and written inspection records product inspection after final packaging in No written standards but had inspection reports 1 place? Have the procedures but no inspection records It’s not necessary to carry out the inspection Other Is there a clear procedure for handling Has the clear procedure and followed records customer complaints? Has the procedure but no written records. 2 No written procedures or records. Other Can the finished/packaged product be traced Have the procedures to trace the raw materials. by lot identification to the appropriate raw Can trace main materials 3 materials test reports? Can trace production date. Can’t trace products Other Are corrective & preventive actions mechanism established and implemented Has the clear procedure and followed records effectively (including the suppliers/ Has the procedure but no written records. 4 sub-contractors control, incoming inspection, No written procedures or records. process control, final inspection and customer Other complaint)? Page No.: 7 of 22 SGS No: QIP-ASI185768 Part C: Product Research & Development Capacity 1.1 Product Research & Development Capacity within 1year staff 1-5 years staff The amount of R&D and relevant working experience. 6-10 years staff over 10 years
Load more

Recommended publications
  • Efficacy Evaluation on the Color Doppler Ultrasound, Multislice Spiral CT Combined with Serum Markers in Diagnosis of Primary Hepatic Carcinoma
    Iran J Public Health, Vol. 50, No.8, Aug 2021, pp.1603-1612 Original Article Efficacy Evaluation on the Color Doppler Ultrasound, Multislice Spiral CT Combined with Serum Markers in Diagnosis of Primary Hepatic Carcinoma Xiaolan Zhao 1, Yifang Xia 2, Chunjing Li 2, *Dapeng Wang 3 1. Department of Ultrasound, Yantaishan Hospital, Yantai 264000, China 2. Department of Imaging, Zhangqiu District People’s Hospital, Jinan 250200, China 3. Department of Imaging, the Affiliated Hospital of China University of Petroleum (East China), Qingdao 266580, China *Corresponding Author: Email: [email protected] (Received 22 Nov 2020; accepted 09 Dec 2020) Abstract Background: The efficacy of color Doppler ultrasound, multislice spiral CT combined with serum alpha- fetoprotein (AFP) and alpha-fetoprotein heterogeneity (AFP-L3) in the diagnosis of primary hepatic carcino- ma was evaluated. Methods: Seventy-nine patients with primary hepatic carcinoma (PHC group) and 50 patients with benign liver lesions (benign control group) admitted in Yantaishan Hospital (Yantai, China) from January 2016 to December 2018 were selected. The liver was scanned by color Doppler ultrasound and multiple multislice spi- ral CT. The serum AFP and AFP-L3 levels were detected by electrochemiluminescence. The value of color Doppler ultrasound, multislice spiral CT combined with serum AFP and AFP-L3 in diagnosis of primary liver cancer was retrospectively analyzed. Results: The color Doppler flow imaging (CDFI) showed a high-speed and high-resistance spectrum. The serum AFP and AFP-L3 levels of patients with primary hepatic carcinoma were significantly higher than those of the benign control group were (U=138.000 and 155.500, P=0.000 and 0.000), P<0.01.
    [Show full text]
  • Property Valuation Report
    THIS DOCUMENT IS IN DRAFT FORM, INCOMPLETE AND SUBJECT TO CHANGE AND THAT THE INFORMATION MUST BE READ IN CONJUNCTION WITH THE SECTION HEADED “WARNING” ON THE COVER OF THIS DOCUMENT APPENDIX III PROPERTY VALUATION REPORT The following is the text of a letter, summary of values and valuation certificates prepared for the purpose of incorporation in this document received from AVISTA Valuation Advisory Limited, an independent valuer, in connection with its valuation as at 30 April 2021 of the property interest held by the Group. [*] 2021 The Board of Directors Runhua Property Technology Development Inc 6th Floor, Building No. 1 Lemeng Center, No. 28988 Jingshi Road, Huaiyin District, Jinan City, Shandong Province, the People’s Republic of China (the “PRC”) Dear Sirs / Madams, INSTRUCTIONS In accordance with the instructions of Runhua Property Technology Development Inc (the “Company”) and its subsidiaries (hereinafter together referred to as the “Group”) for us to carry out the valuation of the property interests located in the PRC held and rented by the Group. We confirm that we have carried out inspection, made relevant enquiries and searches and obtained such further information as we consider necessary for the purpose of providing you with our opinion of the market value of the property interests as at 30 April 2021 (the “Valuation Date”). VALUATION STANDARDS In valuing the property interests, we have complied with all the requirements set out in Chapter 5 and Practise Note 12 of the Rules Governing the Listing of Securities issued by The Stock Exchange of Hong Kong Limited (the “Listing Rules”), RICS Valuation — Global Standards 2020 published by the Royal Institution of Chartered Surveyors (“RICS”) and the International Valuation Standards published from time to time by the International Valuation Standards Council.
    [Show full text]
  • Free PDF Download
    European Review for Medical and Pharmacological Sciences 2021; 25: 3226-3234 LncRNA PRNCR1 aggravates the malignancy of oral squamous cell carcinoma by regulating miR-326/FSCN1 axis D.-K. LIU1, Y.-J. LI2, B. TIAN3, H.-M. SUN4, Q.-Y. LI5, B.-F. REN6 1Department of Stomatology, Yantaishan Hospital, Yantai, Shandong Province, China 2Department of Emergency Internal Medicine, Qingdao Municipal Hospital, Qingdao, Shandong Province, China 3Department of Clinical Laboratory Medicine, People’s Hospital of Rizhao, Rizhao, Shandong Province, China 4Hospital Infection-Control Department, Zhangqiu District People’s Hospital, Jinan, Shandong Province, China 5Imaging Center, Zhangqiu District People’s Hospital, Jinan, Shandong Province, China 6Medical Insurance Department, Zhangqiu District People’s Hospital, Jinan, Shandong Province, China Dekuan Liu and Yongjun Li contributed equally Abstract. – OBJECTIVE: The important regu- Introduction latory mechanism of lncRNA PRNCR1 has been emphasized in malignant tumors. However, the In recent years, oral cancer has been threaten- role of lncRNA PRNCR1 remains unclear in oral ing our health and is one of the most serious oral squamous cell carcinoma (OSCC). The purpose diseases. Oral cancer is more common in men, of this study is to reveal the role of lncRNA PRN- and the most common is oral squamous cell car- CR1 in OSCC. 1 PATIENTS AND METHODS: RT-qPCR was cinoma (OSCC) . The etiology of oral cancer is used to detect mRNA expression. The function- unclear and may be related to long-term smoking al mechanism of lncRNA PRNCR1 in OSCC was and alcohol abuse, poor oral hygiene, malnu- investigated by CCK-8, transwell and Luciferase trition, leukoplakia and erythema2.
    [Show full text]
  • Circnrip1 Modulates the Mir-515-5P/IL-25 Axis to Control 5-Fu and Cisplatin Resistance in Nasopharyngeal Carcinoma
    Drug Design, Development and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH CircNRIP1 Modulates the miR-515-5p/IL-25 Axis to Control 5-Fu and Cisplatin Resistance in Nasopharyngeal Carcinoma This article was published in the following Dove Press journal: Drug Design, Development and Therapy Junwu Lin1,* Background: The development of drug resistance leads many NPC patients to experience Hong Qin2,* disease relapse following the completion of chemotherapy. It is thus essential that the Yue Han3 mechanistic basis for such chemoresistance be clarified in an effort to identify approaches Xinghua Li4 to sensitizing NPC tumors to treatment with cisplatin and related agents. YuJuan Zhao5 Methods: A qRT-PCR approach was used to measure the expression of circNRIP1 in NPC, while luciferase assays were used to identify interactions with downstream targets of Guangsheng Zhai 6 circNRIP1 activity including miR-515-5p and IL-25. CCK8 assays were also utilized to 1Department of Otolaryngology, Central detect IC50 values for cisplatin and 5-Fu. Hospital, Qingdao, Shandong, People’s Republic of China; 2Department of Results: The expression of circNRIP1 was significantly increased in the serum of chemore­ Otolaryngology, Women and Children’s sistant NPC patients. At a functional level, we determined that circNRIP1 is able to sequester Hospital, Qingdao, Shandong, People’s miR-515-5p, thereby inhibiting its ability to post-transcriptionally suppress IL-25 expression. Republic of China; 3Department of Urology, Zhangqiu District People’s We observed a significant negative correlation between the expression of miR-515-5p and Hospital, Jinan, Shandong, People’s circNRIP1 in serum samples from chemoresistant NPC patients, consistent with a functional 4 Republic of China; Department of interaction between these two factors.
    [Show full text]
  • Research Article Effect of Entecavir Combined with Adefovir Dipivoxil on Clinical Efficacy and TNF-Α and IL-6 Levels in Patients with Hepatitis B Cirrhosis
    Hindawi Journal of Oncology Volume 2021, Article ID 9162346, 5 pages https://doi.org/10.1155/2021/9162346 Research Article Effect of Entecavir Combined with Adefovir Dipivoxil on Clinical Efficacy and TNF-α and IL-6 Levels in Patients with Hepatitis B Cirrhosis Yonghuan Yu ,1 Xinfeng Cui ,2 Jingjing Zhao ,3 Ting Jia ,4 Baofeng Ren ,5 and Xiaoyan Zhang 6 1Department of Blood Transfusion, Yantaishan Hospital, Yantai 264000, China 2Department of Stomatology, Chengyang People’s Hospital, Chengyang 266109, China 3Department of Surgery, Zhangqiu District People’s Hospital, Jinan 250200, China 4Department of Gynaecology, Zhangqiu District People’s Hospital, Jinan 250200, China 5Medical Insurance Department, Zhangqiu District People’s Hospital, Jinan 250200, China 6PIVAS, Weifang People’s Hospital, Weifang 261041, China Correspondence should be addressed to Xiaoyan Zhang; [email protected] Received 3 June 2021; Accepted 17 August 2021; Published 25 August 2021 Academic Editor: Muhammad Wasim Khan Copyright © 2021 Yonghuan Yu et al. -is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective. -e purpose of the study was to investigate the effect of entecavir combined with adefovir dipivoxil on clinical efficacy and TNF-α and IL-6 levels in patients with hepatitis B cirrhosis. Methods. A total of 100 patients with hepatitis B cirrhosis admitted to our hospital between January 2018 and June 2019 were randomly selected and divided into the control group (n � 50) and experimental group (n � 50) according to the order of admission.
    [Show full text]
  • Everbright Water Secures Ji'nan Zhangqiu Waste Water
    Singapore Exchange Securities Trading Limited, Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. CHINA EVERBRIGHT WATER LIMITED 中國光大水務有限公司 (Incorporated in Bermuda with limited liability) (Hong Kong Stock Code: 1857) (Singapore Stock Code: U9E) OVERSEAS REGULATORY ANNOUNCEMENT EVERBRIGHT WATER SECURES JI’NAN ZHANGQIU WASTE WATER TREATMENT (PLANT 4) PPP PROJECT IN SHANDONG PROVINCE This overseas regulatory announcement is issued pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. Please refer to the attached press release which has been published by China Everbright Water Limited (the “Company” or “Everbright Water”) on the website of the Singapore Exchange Securities Trading Limited on 27 April 2020. By Order of the Board China Everbright Water Limited An Xuesong Executive Director and Chief Executive Officer Hong Kong, 27 April 2020 As at the date of this announcement, the board of directors of the Company comprises: (i) a non-executive director, Mr. Wang Tianyi (Chairman); (ii) two executive directors, namely Mr. An Xuesong (Chief Executive Officer) and Mr. Luo Junling; and (iii) four independent non-executive directors, namely Mr. Zhai Haitao, Mr. Lim Yu Neng
    [Show full text]
  • A Regional Sustainable Intensive Land Use Evaluation Based on Ecological Constraints: a Case Study in Jinan City
    sustainability Article A Regional Sustainable Intensive Land Use Evaluation Based on Ecological Constraints: A Case Study in Jinan City Qian Qian 1, Haiyan Liu 2,* and Xinqi Zheng 1,3,* 1 School of Information Engineering, China University of Geosciences, Beijing 100083, China; [email protected] 2 School of Economic and Management, China University of Geosciences, Beijing 100083, China 3 Polytechnic Center for Territory Spatial Big-Data, MNR of China, Beijing 100036, China * Correspondence: [email protected] (H.L.); [email protected] (X.Z.) Received: 17 January 2019; Accepted: 3 March 2019; Published: 8 March 2019 Abstract: Intensive development is a sign of human social progress, and moderate intensification is a continuously pursued goal. However, how to conduct a moderately intensive land use evaluation remains a challenge. To solve this problem, this research proposes the concept of sustainable intensification variable and develops a sustainable intensification variable model to determine the appropriate interval of regional intensive land use and evaluate the intensification of land use. The evaluation method of the sustainable intensification variable model is based on the principle and method of the intensification variable, and the regional sustainable development evaluation factors in the model are revised based on rational land use and ecological constraints. To verify the rationality of the model and systematically evaluate the intensification of land use in the city of Jinan, this method was tested using land use data and social economic data on Jinan from 2001, 2011, and 2015. The results show that the model has a high accuracy in judging the moderately intensive interval of regional land use and evaluating intensive land use, and has important reference value for regional sustainable development decision-making.
    [Show full text]
  • December 14, 2020 Shandong Shengquan New Material Co., Ltd
    December 14, 2020 Shandong Shengquan New Material Co., Ltd. ℅ Shelley Li Director Shanghai Landlink Medical Information Technology Co., Ltd. Room 703, 705, Baohua International Plaza, West Guangzhong Road 555, Jingan Shanghai, 200071 China Re: K201629 Trade/Device Name: Medical Face Mask Regulation Number: 21 CFR 878.4040 Regulation Name: Surgical Apparel Regulatory Class: Class II Product Code: FXX Dated: December 4, 2020 Received: December 9, 2020 Dear Shelley Li: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
    [Show full text]
  • Original Article Ultrastructural Pathological Alterations in Ocular Muscles in a Cat Model with Exotropia
    Int J Clin Exp Pathol 2017;10(7):7559-7564 www.ijcep.com /ISSN:1936-2625/IJCEP0053522 Original Article Ultrastructural pathological alterations in ocular muscles in a cat model with exotropia Huimin Gong1,2, Guixiang Liu2, Yidan Wang3, Wei Wei4, Cong Li1 1Department of Ophthalmology, The Affiliated Municipal Hospital of Qingdao University, Qingdao, China; 2Depart- ment of Ophthalmology, The Affiliated Hospital of Qingdao University, Qingdao, China;3 Department of Ophthalmol- ogy, Yeda Hospital of Yantai, Yantai, China; 4Department of Ophthalmology, People’s Hospital of Zhangqiu District, Jinan, China Received March 22, 2017; Accepted May 27, 2017; Epub July 1, 2017; Published July 15, 2017 Abstract: To study the ultrastructural alterations of the ocular muscles in a cat model with exotropia. A total of 18 cats (4-6 weeks old) were included in the study and randomly divided into experimental group (n=12) and sham group (n=6). The experimental group underwent surgery to generate the exotropia model. 4 and 2 cats of each group were euthanatized respectively, at the end of 1st month, 2nd month, and 3rd month after strabismus surgery, and the right medial rectus muscles were harvested, followed by staining and examination of ultrastructural changes under electron microscope. The proportion of irregularly arranged myofibrils and abnormal Z lines, and the number of mitochondria per unit area were recorded. In experimental group myofibril irregular arrangement percentage was shown to be markedly higher than that of the sham group (t=2.882, 6.085, 8.641, P<0.05). There was significant difference of abnormal rate of Z line in the medical rectus muscles between the experimental and sham group at the 2nd and 3rd month after surgery (t=8.230, 34.272, P<0.01).
    [Show full text]
  • Effects of Tetrandrine Combined with Acetylcysteine on Exercise Tolerance, Pulmonary Function and Serum TNF-Β1 and MMP-7 in Silicosis Patients
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 19: 2195-2201, 2020 Effects of tetrandrine combined with acetylcysteine on exercise tolerance, pulmonary function and serum TNF-β1 and MMP-7 in silicosis patients JING ZHANG1*, YINGCHUN WANG2*, SHUJUAN ZHANG3, JING LI4 and HONG FANG5* 1Department of Pharmacy, Maternal and Child Health Care Hospital of Zhangqiu District, Jinan 250200; 2Department of Pharmacy, Yantaishan Hospital, Yantai 264000; 3Occupational Disease Department, Branch of Tai'an City Central Hospital, Tai'an 271000; 4Department of Surgery, The People's Hospital of Zhangqiu Area, Jinan 250200; 5Department of Hepatobiliary Surgery, Weifang Traditional Chinese Hospital, Weifang 261041, P.R. China Received May 8, 2019; Accepted October 30, 2019 DOI: 10.3892/etm.2020.8431 Abstract. The aim of the study was to investigate the Before treatment, there was no significant difference in effects of tetrandrine combined with acetylcysteine on exer- serum TGF-β1 and MMP-7 expression levels between the cise tolerance, pulmonary function, transforming growth two groups (P>0.05). By contrast, after treatment, the levels factor-β1 (TGF-β1) and matrix metalloproteinase 7 (MMP-7) in the two groups were significantly decreased, with the levels in silicosis patients. A retrospective analysis was performed in the study group being significantly lower than that the on 149 silicosis patients admitted to the Maternal and Child control group (P<0.05). In conclusion, tetrandrine combined Health Care Hospital of Zhangqiu District between August, with acetylcysteine can improve pulmonary function and 2015 and September, 2017. Of the 149 patients, 70 patients exercise tolerance of patients with silicosis by inhibiting the treated with acetylcysteine comprised the control group, and expressions of TGF-β1 and MMP-7, thus improving clinical 79 treated with tetrandrine combined with acetylcysteine efficacy.
    [Show full text]
  • Download 4.37 MB
    Initial Environmental Examination Project Number: 51418-001 September 2018 Proposed Loan for People’s Republic of China: Air Quality Improvement in the Greater Beijing– Tianjin–Hebei Region—Shandong Clean Heating and Cooling Project (East Jinan Low-Emission Combined District Heating and Cooling Component) Prepared by Jinan Heating Group for the Asian Development Bank CURRENCY EQUIVALENTS (as of 12 September 2018) Currency Unit – Chinese Yuan (CNY) CNY1.00 = € 0.1258 €1.00 = CNY 7.9482 ABBREVIATIONS ADB Asian Development Bank AP Affected Person AQI Air Quality Index CHP Combined heat and power EA Executing Agency EHS Environment, Health and Safety EIA Environmental Impact Assessment EMoP Environmental Monitoring Plan EMP Environmental Management Plan EMS Environmental Monitoring Station EPB Environmental Protection Bureau EPL Environmental Protection Law FSR Feasibility Study Report FGD Flue-gas Desulfurization GDP Gross Domestic Product GHG Green House Gas GIP Good International Practice GIIP Good International Industrial Practice GRM Grievance Redress Mechanism HSP Heat source plant IA Implementing Agency IEE Initial Environmental Examination IT Interim Target JHG Jinan Heating Group JTPC Jinan Thermal Power Co,. Ltd MAC Maximum Acceptable Concentration MEE Ministry of Ecology and Environment MEP Ministry of Environmental Protection MSDS Material Safety Data Sheet PAM Project Administration Manual PCR Physical Cultural Resources PPE Personnel Protective Equipment PPTA Project Preparatory Technical Assistance PRC People’s Republic of
    [Show full text]
  • Annual Report 2018
    CHINA VANKE CO., LTD.* (a joint stock company incorporated in the People’s Republic of China with limited liability) (Stock code: 2202) ANNUAL REPORT 2018 *For identification purpose only Important Notice: 1. The Board, the Supervisory Committee and the Directors, members of the Supervisory Committee and senior management of the Company warrant that in respect of the information contained in 2018 Annual Report (the “Report”, or “Annual Report”), there are no misrepresentations, misleading statements or material omission, and individually and collectively accept full responsibility for the authenticity, accuracy and completeness of the information contained in the Report. 2. The Report has been approved by the 18th meeting of the 18th session of the Board (the “Meeting”) convened on 25 March 2019. Mr. LIN Maode, vice chairman of the Board and a non-executive director, did not attend the Meeting due to business engagement, and had authorized Mr. CHEN Xianjun, a non-executive director, to attend the Meeting and execute voting rights on his behalf. All other directors attended the Meeting in person. 3. The Company’s proposal on dividend distribution for the year of 2018: The total amount of cash dividends proposed for distribution for 2018 will be RMB11,811,892,641.07 (inclusive of tax), accounting for 34.97% of the net profit for the year attributable to equity shareholders of the Company for 2018, without any bonus shares or transfer of equity reserve to the share capital. Based on the Company’s total number of 11,039,152,001 shares at the end of 2018, a cash dividend of RMB10.7 (inclusive of tax) will be distributed for each 10 shares.
    [Show full text]